美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Celladon Corporation

1.15

0.0000

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：1.15

开：1.15

低：1.15

收：1.15

数据加载中...

总览公司新闻公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻

信达生物IBI343（CLDN 18.2抗体药物偶联物）在澳大利亚完成首例受试者给药

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/CLDN"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLDN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDN\",,,,,undefined,":{"symbol":"CLDN","market":"US","secType":"STK","nameCN":"Celladon Corporation","latestPrice":1.15,"timestamp":1459195200000,"preClose":1.15,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"盘前交易","change":0,"latestTime":"05-21 04:29:00 EDT","open":1.15,"high":1.15,"low":1.15,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747834200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.15,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDN\",,,,,undefined,":{"symbol":"CLDN","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":1.15,"amplitude":0,"preClose":1.15,"low":1.15,"week52Low":0.86,"pbRate":"--","week52High":26.17,"institutionHeld":0,"latestPrice":1.15,"eps":0,"divideRate":0,"volume":0,"delay":0,"open":1.15},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CLDN\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLDN\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2279242198","title":"信达生物IBI343（CLDN 18.2抗体药物偶联物）在澳大利亚完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2279242198","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2279242198?lang=zh_cn&edition=fundamental","pubTime":"2022-10-31 08:00","pubTimestamp":1667174400,"startTime":"0","endTime":"0","summary":"IBI343是重组人源抗CLDN18.2 ADC，与表达CLDN18.2的肿瘤细胞结合后，可发生CLDN18.2依赖性ADC内化，并释放毒素药物引起DNA损伤，导致肿瘤细胞凋亡。我们很高兴IBI343在澳大利亚的临床1期研究已完成首例受试者给药，期待IBI343在晚期实体瘤试者中获得积极结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/3918251_ZH18251_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1589","BK1161","BK1583","01801","IVBIY","CLDN"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLDN\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLDN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLDN\",market:\"US\",delay:false,,,undefined,":{}}}